irsogladine

Irsogladine is a small molecule drug developed as a mucosal protective agent for the treatment of peptic ulcer disease, acute gastritis, and to prevent gastric mucosal injury. It acts primarily by enhancing gastric mucosal defense mechanisms rather than inhibiting acid secretion. Its mechanism involves non-selective inhibition of phosphodiesterase isozymes (notably PDE4), leading to increased intracellular cyclic adenosine monophosphate (cAMP) levels in gastric cells. This results in improved intercellular communication, increased blood flow to the gastric mucosa, anti-inflammatory effects through suppression of proinflammatory cytokines (such as TNF-α, IL-1β, and IL-8), and protection against various forms of gastrointestinal injury including those induced by NSAIDs or aspirin. Irsogladine was developed in Japan by Mitsubishi Tanabe Pharma and has been shown to be effective in both experimental models and clinical studies for protecting the gastrointestinal tract[1][4][6][8].

Brand names

GaslonGaslon N

Other names

irsogladine maleate